Search PubMed⌕ Search

Biomedical subjects

T Klein

Publications and source records attributed to T Klein.

At least 235 records · Page 13Linked to original sources
PubMed1982

[Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].

A randomized trial was done in 98 post-menopausal women with breast cancer. Hormonal receptors had not been assayed in any patient. Patients were given hormonal therapy with tamoxifen and drostanolone propionate (n = 34), or chemotherapy with the CMF protocol (n = 30), or a combination of both (n = 34). The results are in favour of hormonal therapy alone, which gave the best immediate objective responses, the least adverse side-effects, and possibly improved survival rates.

Androstanols↗
PubMed1981

Changes in maternal serum total and free androgen levels in early pregnancy: lack of correlation with fetal sex.

The fetal testis actively produces androgens during early gestation. To determine whether this fetal production of androgens might be reflected by levels of androgens in maternal serum, which might then be a useful test for antenatal fetal sex determination, we measured serum testosterone (total and free) and serum dihydrotestosterone in 83 pregnant women whose fetuses ranged from 4 to 20 weeks in age. For no maternal serum androgen measured was there a significant difference between women carrying a male fetus and those carrying a female fetus, even when this comparison was limited to various 4-week subintervals or fetal age. Total serum testosterone correlated directly with fetal age (r = 0.341, p less than 0.005), but serum dihydrotestosterone did not (r = 0.146, p = NS). Inverse correlations with fetal age were observed for percentage free testosterone (r = -0.531, p less than 0.001) as well as absolute serum free testosterone (r = -0.349, p less than 0.005). We conclude that maternal serum androgen levels are not useful for antenatal fetal sex determination in early pregnancy. The reason for the progressive fall in serum free testosterone, and presumably androgen production, during early gestation remains obscure.

Dihydrotestosterone↗
PubMed1981

[Randomized trial of vincristin-methotrexate-bleomycin and cis-platin or detorubicin for advanced head and neck cancer (author's transl)].

In a randomized multicenter trial, 151 patients, with advanced epidermoid carcinoma of the head, neck and oesophagus, were treated with an association of vincristin, methotrexate, bleomycin and cis-platin (group I) or detorubicin (group II). Prognostic factors were equally distributed for the both groups. Partial or complete responses were obtained in 22 patients of group I (29 p. cent) and 9 in group II (12 p. cent, p less than 0.05). Objective response rates were higher in untreated patients or those in good condition but the difference was not statistically significant. Five probably treatment induced deaths (3 p. cent) were observed. Treatment was stopped in 2 patients (15 p. cent) for haematological, general or digestive toxicity. This trial confirms the efficacy of vincristin, methotrexate, bleomycin and cis-platin for advanced head and neck carcinomas.

Adult↗
PubMed1979

Folate nutrition and growth in infancy.

The effect of suboptimal folate nutrtion on the growing infant was studied in a population of infants fed a diet based on boiled, pasteurised cows' milk. One group of infants received a daily supplement of 1 mg folic acid from age 2 months, while the other group received a placebo. The infants were seen at bimonthly intervals. In the supplemented group the red cell folate level had increased to twice its pretreatment value by 4 months, and remained at this high level to the end of the first year. Hb concentration and incidence of anaemia were similar in both groups. The incidence of infection in the two groups did not differ. Weights and lengths attained at 6 months, and the rate of gain from 2 to 6 months were higher in infants whose folate levels were above the median value than in those below it. In the second half of the first year the differences between the two groups were no longer evident.

Body Height↗
PubMed1978

[Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].

Adding duborimycin to the association of vincristine + DTIC in the treatment of malignant melanoma produces therapeutic results interesting but not statistically significant and not counter-balancing the toxic side effects. This study confirms the lack of positive results of polychemotherapy in melanoma as compared to treatment by an efficacious single drug therapy (DTIC); it also emphasizes the necessity of randomized studies so that valuable comparisons may be done.

Antibiotics, Antineoplastic↗
PubMed1978

[Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].

Rubidazone is a semisynthetic antibiomitotic close to daunorubicin and doxorubicin. Fifty two patients with various advanced cancers received rubidazone intravenously at the initial unitary dose of 200 mg/m2 in a single injection at three week intervals; this base line dosage had been adapted in function of leuko-platelet variations observed between the injections. An objective improvement was noted in 18 patients out of 51 evaluable patients (34% of the cases), 6 times the regression of tumoral volume was greater than 50 per cent but not complete (3 breast adenocarcinomas and 3 lymphomas). Manifestations of intolerance-toxicity were minor on the haematologic side (32%); however, they were relatively frequent from the digestive (63%) and general (82%) point of view; symptoms of cardiac disturbances (21%), responsible for the discontinuation of the chemotherapy, necessitate careful attention in the management of the treatment. The comparison of the results of this trial with those obtained by trials using other drugs belonging to the same chemical family don't show, for solid tumors, any difference in efficacy between rubidazone, daunorubicin or duborimycin; however, the difference is very striking with doxorubicin which showed more efficacy (6.5% as 29% of regression greater than 50%). Owing to the conditions of admission and the very strict criteria of analysis in this study, it would seem useful to go into details regarding the interest of rubidazone in lymphomas (only one failure has been recorded out of 6 treated cases).

Adenocarcinoma↗
PubMed1977

[Polychemotherapy of advanced breast cancer. Triple combination with doxorubicin. Analysis of 209 observation].

Two hundred and nine patients with breast cancer in an advanced stage were treated according to a chemotherapeutic regimen associating doxorubicin, vincristine and methotrexate, administered in courses of 5 days every three weeks. This analysis deals only with the short range results; they confirm those of a previous randomized study. A global objective response was obtained in 187 cases (89%) and a measurable regression of the lesions in 150 cases (71%); in these later cases 90 (43%) had a regression of more than 50 per cent. The most striking effects, often rapidly observed, involve sites which are not generally sensitive: liver (40%), pleura (24%) and bone (only 6%, but 8 times out of 10 a definite action on the pain syndrome). Side effects were, on the whole, acceptable (only one severe hematologic complication); however, the risk of myocardiac toxocity due to the accumulation of doxorubicin limits the utilization of this association. It thus needs to be relayed by other drug regimens which are included in a program of long term action, but has interesting characteristics as induction chemotherapy.

Adult↗